Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals

Abstract

excised down to the level of the deep muscle fascia from the knee to the dorsum of the foot. The wound was covered with 12-to 16/1000-inch split thickness skin grafts harvested from the ipsilateral leg. For those who underwent elective toe amputations, toe disarticulation at the metatarsalphalangeal joint was combined with removal of the articular cartilage from the metatarsal heads. Average follow-up was 3.5 years. During follow-up, 20% of the patients who underwent combined Charles procedure and elective toe amputation experienced recurrent bouts of cellulitis of the foot or leg, 50% required at least one operation for excision of crypts within the skin-grafted areas, and none required more proximal amputations. In those patients who did not undergo elective toe amputation, 83% had multiple episodes of foot or leg cellulitis and 54% underwent at least one operation for foot or leg excision of crypts, and 80% subsequently required amputation of toes secondary to chronic ulceration, infection, or drainage from web spaces. Two patients required more proximal amputation, including one below knee amputation.Comment: Those who care for patients with advanced lymphedema realize that appropriate foot hygiene is the mainstay to reduce interdigital entry lesions, but such care can be ineffective in the terminal stages of lymphedema. These patients have deformity of the toes and limited mobility. The increased weight and volume of the affected limbs prevents them from performing appropriate foot hygiene. This is an aggressive approach to the treatment of end-stage lymphedema. Nevertheless, if a decision has been made to perform a Charles procedure, the authors' data suggest the addition of toe amputations is reasonable.

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

“…The methods used in L-TAP 2 have been described previously [8]. In brief, patients were eligible if they were aged !20 years, and if they had been treated with the same lipid-lowering therapy for !3 months.…”

“…The Lipid Treatment Assessment Project 2 (L-TAP 2) was a multicenter survey of lipid goal attainment in dyslipidemic patients who were on stable lipid-lowering therapy at investigation sites in 9 countries (Canada, Brazil, Mexico, the USA, France, Spain, the Netherlands, South Korea, and Taiwan) between September 2006 and April 2007 [8]. This current pre-specified analysis of the L-TAP 2 survey describes the attainment of non-HDL-C goals according to the level of risk and compared with LDL-C goal attainment in the whole study population, as well as according to gender, baseline plasma TG levels ( 200 mg/dL vs. >200 mg/dL), and world region.…”

Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS)

“…Statins are the mainstay of lipid-lowering drug (LLD) therapy and have been shown to reduce both LDL-C levels and CV risk in clinical trials [9][10][11][12][13][14][15][16] . Despite the significant increase in the number of patients treated with statins and other LLDs over the past decade, surveys have shown that relatively few individuals eligible for treatment attain their recommended LDL-C level [17][18][19] . …”

“…575 LDL-C after 12 months 17) . However, the Lipid Treatment Assessment Project 2 (L-TAP2) study 19) , reported a higher rate of LDL-C goal attainment than the combined CEPHEUS studies. The L-TAP2 study was conducted in nine countries across Europe (France, Netherlands, and Spain), the Americas (USA, Canada, Brazil, and Mexico) and Asia (South Korea and Taiwan), and 73% of 9955 evaluated patients were shown to have attained their LDL-C goal.…”

Ambulatory Treatment Gaps in Patients with Ischemic Stroke or Transient Ischemic Attack

“…A considerable amount of research exploring treatment gaps has been conducted in patients with CAD. [17][18][19][20][21] Research in patients with NCIS or TIA appears to demonstrate similar findings and highlights important treatment gaps among this population. Although there are considerably fewer studies by which to draw conclusions compared with the CAD literature, studies report that …”